New York, NY — January 7, 2014
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) today announced that its President and Chief Executive Officer Christopher U. Missling, PhD, will participate in the 7th Annual OneMedForum: Investing in Healthcare 2014 (“OneMedForum”) and the Noble Financial Capital Markets (“Noble”) Tenth Annual Equity Conference.
OneMedForum is recognized as a leading growth company conference. Each year, it showcases promising and innovative microcap public companies in healthcare and life sciences. Dr. Missling has been enlisted to make a presentation on Anavex, including an overview of ANAVEX PLUS, a promising, potentially novel combination drug for Alzheimer’s disease. ANAVEX PLUS combines ANAVEX 2-73 with Aricept® (donepezil), the best-selling Alzheimer’s drug with annual global sales of $4 billion.
WHAT: Anavex Corporate Presentation at OneMedForum WHEN: January 14, 2014 at 9:10 a.m. PT WHERE: The Westin Market Street, San Francisco
Dr. Missling is also scheduled to make a corporate presentation at Noble’s Tenth Annual Equity Conference. Interested investors may view Dr. Missling’s presentation to Noble attendees via webcast.
WHAT: Anavex Corporate Presentation at Noble Equity Conference WHEN: January 21, 2014 at 11:30 a.m. ET WHERE: Sandpiper Bay, South Florida WEBCAST LINK: http://noble.mediasite.com/mediasite/Play/2882aefd8ef24d20853a32c6b217e6031d
ANAVEX 2-73 is an orally available drug candidate developed to potentially modify Alzheimer’s disease rather than temporarily address its symptoms. It has a clean Phase 1 data profile and shows reversal of memory loss (anti-amnesic properties) and neuroprotection in several models of Alzheimer’s disease.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (www.anavex.com) is a clinical stage biopharmaceutical company engaged in the development of novel drug candidates to treat Alzheimer’s, CNS diseases and various types of cancer. ANAVEX 2-73, an orally available drug candidate developed to treat Alzheimer’s through potential disease modification, has undergone an initial Phase 1 human clinical trial and was well tolerated in doses up to 55mg. Results from pre-clinical studies indicate that ANAVEX 2-73 demonstrates anti-amnesic and neuroprotective properties. A highly encouraging synergistic effect has also been observed between ANAVEX 2-73 and Aricept® (donepezil). The combined therapeutics produced up to 80% greater reversal of memory loss in Alzheimer’s disease models versus when the drugs were used individually. Anavex is a publicly traded corporation quoted as AVXL.
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information
Anavex Life Sciences Corp. Research & Business Development Email: email@example.com
Shareholder & Media Relations Toll-free: 1-866-505-2895 Outside North America: +1 (416) 489-0092 Email: firstname.lastname@example.org www.anavex.com